Repligen (RGEN) is a "bioprocessing-focused life sciences company" which sounds way above my pay grade. Shares of RGEN soared from $165 in May to short of $330 in late September. A double in five months has my attention. Let's check out the charts.
More from Investing
Many tech valuations are now back to 2016 or 2017 levels, and quite a few contrarian indicators point to extreme bearishness.
No one trusts a bounce to last at this point, and they simply are hoping for some relief from the unpleasant action.
APD got a "Buy" recommendation, but my analysis doesn't jibe.
Here's our updated bullish strategy on PXD.